Q BioMed, Inc. CEO Discusses Recently Announced International Market Authorizations and Expansion in to South and Central America and Asia for Q BioMed’s Strontium89, its FDA Approved Drug for the Non-Opioid Treatment of Metastatic Cancer in the Bone
September 22, 2020 07:00 ET
|
Q BioMed Inc.
AUSTIN, Texas, Sept. 22, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Q BioMed Inc. (“the Company”) (OTCQB: QBIO), a commercial...
Q BioMed, Inc. CEO Discusses Recently Announced Global Distribution Partnership with Caligor Coghlan Pharma Services in Audio Interview with SmallCapVoice.com
July 09, 2020 08:00 ET
|
Q BioMed Inc.
AUSTIN, Texas, July 09, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Q BioMed Inc. (“the Company”) (OTCQB: QBIO), a commercial...
Denis Corin, CEO, of Q BioMed Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com
April 30, 2020 08:00 ET
|
Q BioMed Inc.
NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and Q BioMed Inc. (OTCQB: QBIO) (the "Company"), a commercial stage biotechnology company, announced today that a new audio...
Q BioMed Announces Updates on Commercialization of Non-Opioid Metastatic Cancer Pain Drug
July 11, 2019 08:32 ET
|
Q BioMed Inc.
NEW YORK, July 11, 2019 (GLOBE NEWSWIRE) -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, is pleased to announce the latest updates on its non-opioid therapy for the debilitating...
Q BioMed Files for Orphan Drug Designation with U.S. FDA for Autism Spectrum Disorder Subtype
June 28, 2019 08:32 ET
|
Q BioMed Inc.
Currently no effective treatment exists for the 20,000 children in the U.S. and 250,000 born worldwide each year with pediatric minimally verbal autism (PMVA) NEW YORK, June 28, 2019 (GLOBE...
Q BioMed Advances QBM-001 for the Treatment of Autism Spectrum Disorder Subtype
June 04, 2019 08:32 ET
|
Q BioMed Inc.
No effective treatment exists for the estimated 250,000 children born worldwide each year with pediatric minimally verbal autism (PMVA), of those approximately 20,000 are born in the U.S. Orphan Drug...
QBioMed Research Partner Mannin Research to Attend ARVO 2019 Annual Meeting
April 24, 2019 08:01 ET
|
Q BioMed Inc.
NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today its technology partner Mannin Research will be attending ARVO 2019 the...
In a Major Breakthrough, Q BioMed Discovers First Biomarkers for Pediatric Nonverbal Autism Subgroup
April 10, 2019 08:35 ET
|
Q BioMed Inc.
Marks the first time a company has identified biomarkers that hold the potential to stratify this subset of patients Study examined 1,953 significant autistic biomarkers, resulting in 2 significant...
Q BioMed and Mannin Research to Develop GDF15 Biomarker Glaucoma Diagnostic Kit Through Collaboration with McMaster University
March 19, 2019 07:00 ET
|
Q BioMed Inc.
Enabling technology to more effectively manage glaucoma progression and patient treatmentServes unmet need - Currently no single examination or diagnostic test is able to accurately predict disease...
Q Biomed Licenses Novel Biomarker for Monitoring Glaucoma Severity and Progression From Washington University
March 11, 2019 08:33 ET
|
Q BioMed Inc.
NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce it has exercised its option to...